Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 28, 2011

Sanofi-Aventis' Iniparib Fails in Phase III Triple-Negative Breast Cancer Trial

  • BiPar Sciences and parent company sanofi-aventis confirmed that a Phase III trial evaluating iniparib (BSI-201) in patients with metastatic triple-negative breast cancer (mTNBC) failed to meet its primary endpoint. The 519-patient study failed to show benefits on overall survival and progression-free survival from adding iniparib to standard chemotherapy comprising gemcitabine and carboplatin.

    The firms say, however, a prespecified analysis of patients treated in the second- and third-line setting did suggest that adding iniparib to chemotherapy led to improvements in overall survival and progression-free survival consistent with those observed in a previous Phase II trial.

    “While this trial did not meet its primary goal, we believe that the improvement in overall survival and progression-free survival in patients in the second-and third-line setting are important findings,” states Debasish Roychowdhury, Ph.D., senior vp and head of sanofi-aventis oncology. “We are conducting an in-depth analysis to gain further insight into these Phase III results.”

    Iniparib is separately undergoing Phase III trials in patients with squamous non-small-cell lung cancer, and Phase II studies in patients with breast, lung, and other cancers. BiPar’s pipeline also includes follow-on PARP inhibitor BSI-401, and an antitubulin agent BSI-302, which has been developed to target cancer cells based on the role of thyroid hormones in cell proliferation and death. Both these candidates are in preclinical development.

Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »